TABLE 1.
Study isolates, susceptibilities, clinical features, and typing results
| Isolate | Origina | Infection type (days of bacteremia on vancomycin) | Source | Phenotypeb | Vancomycin exposure (days)c | Avg vancomycin trough level (μg/ml) (range) | MIC (μg/ml) ford:
|
spa type | Source/reference and comments | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VCM | TEIC | OXA | |||||||||
| Pair 1 | |||||||||||
| JKD6000 | MEL | Endocarditis (13) | BCf | VSSA | 13 | 15.0 (4.0-26.0) | 2.0 | 0.5 | >256 | Type 3 | This study |
| JKD6001 | BC | VISA | 4.0 | 8.0 | >256 | Type 3 | 22 | ||||
| Pair 2 | |||||||||||
| JKD6009 | NZ | Endocarditis (8) | Wound | VSSA | 42 | 11.6 (10.8-12.3) | 1.0 | 0.5 | >256 | Type 3 | This study |
| JKD6008 | BC | VISA | 4.0 | 2.0 | >256 | Type 3 | 22 | ||||
| Pair 3 | |||||||||||
| JKD6021 | MEL | Liver abscess (15) | BC | VSSA | 15 | 5.4 (5.0-5.8) | 1.0 | 0.25 | >256 | Type 3 | This study |
| JKD6023 | BC | VISA | 4.0 | 8.0 | >256 | Type 3 | 22 | ||||
| Pair 4 | |||||||||||
| JKD6052 | BRIS | Endocarditis (32) | BC | VSSA | 32 | NAg (>10.0) | 1.0 | 0.5 | >256 | Type 3 | This study |
| JKD6051 | BC | hVISA | 2.0 | 4.0 | >256 | Type 3 | This study; previous VCM MIC, 4 μg/ml | ||||
| Pair 5 | |||||||||||
| JKD6004 | BRIS | PPMe infection (8) | BC | VSSA | 8 | 16.1 (5.3-30.5) | 1.0 | 0.5 | >256 | Type 574 | This study |
| JKD6005 | BC | hVISA | 2.0 | 4.0 | >256 | Type 574 | 22; previous VCM MIC, 4 μg/ml | ||||
| ATCC 25923 | VSSA | 1.0 | 0.5 | 2 | |||||||
| Mu3 (ATCC 700698) | hVISA | 2.0 | 4.0 | 15 | |||||||
a
MEL, Melbourne, Australia; BRIS, Brisbane, Australia; NZ, New Zealand.
b
Defined by population analysis profile (see Materials and Methods).
c
Number of days of vancomycin exposure between the first and last isolates in each pair.
d
VCM, vancomycin; TEIC, teicoplanin; OXA, oxacillin.
e
PPM, permanent pacemaker.
f
BC, blood culture.
g
NA, incomplete data available; however, all vancomycin serum levels were above 10 μg/ml.